Home / Drug shortages / Dextrose Monohydrate 50% Injection

Dextrose Monohydrate 50% Injection — FDA Drug Shortage

To Be Discontinued — Hospira, Inc., a Pfizer Company

The FDA lists a drug shortage record for Dextrose Monohydrate 50% Injection (injection) from Hospira, Inc., a Pfizer Company with status To Be Discontinued. The shortage was first posted on 11/07/2025.

Shortage Details

Status
To Be Discontinued
Company
Hospira, Inc., a Pfizer Company
Package NDC
0409-4902-34
Dosage Form
Injection
Presentation
Dextrose Monohydrate 50%, Injection, 50% Dextrose Injection 0.5 g/mL; ABBOJECT® Glass Syringe (NDC 0409-4902-34)
Initial Posting
11/07/2025
Revised Date

FDA data resources